Testosterone Enanthate Month-by-Month: Real Results in the First 3 Months

What the trials measured, and when

Hematocrit is the best-quantified effect. A network meta-analysis of 29 placebo-controlled randomized trials (3,393 men) found every formulation raised mean hematocrit, with intramuscular enanthate or cypionate at 4.0% versus placebo (95% CI 2.9% to 5.1%) [1]. A review describes short-acting injectables as carrying the highest incidence of erythrocytosis [7]. The enanthate label lists polycythemia as an adverse reaction [4].

On blood pressure, FDA's February 2025 labeling action states that ambulatory blood pressure studies confirmed an increase with all testosterone products, class-wide. The enanthate label says testosterone products are not recommended in men with uncontrolled hypertension [2][4].

On the hormone axis, 29 healthy men received 200 mg of enanthate weekly for three weeks, together with either placebo or hCG. In the placebo group, LH and FSH fell to 5% and 3% of baseline and intratesticular testosterone fell by 94% [3]. The label describes feedback inhibition of LH and lists oligospermia at high dosages [4].

On blood levels, 20 hypogonadal men in a randomized trial received 250 mg of intramuscular enanthate every 3 weeks for 30 weeks. Their mean trough serum testosterone was always below 10 nmol/L before the next injection [12].

Body composition: trials of 10 to 20 weeks in healthy men

A 10-week trial randomized 43 normal men to four groups: placebo or 600 mg of enanthate weekly, with or without weight training. The testosterone-plus-exercise group gained 6.1 kg of fat-free mass, and mood and behavior did not change in any group [6]. In 61 healthy young men whose own testosterone was suppressed with a GnRH agonist, weekly enanthate at 25, 50, 125, 300 or 600 mg for 20 weeks raised fat-free mass by 3.4, 5.2 and 7.9 kg at the 125, 300 and 600 mg doses. Sexual function, mood and PSA did not change significantly at any dose [5]. Leg press strength and power rose with dose over the same 20 weeks; fatigability did not change [8]. Both trials enrolled men without hypogonadism, so they do not show what a hypogonadal man gains at labeled doses.

In a 39-man study that included an intramuscular reference group, men on weekly subcutaneous enanthate had mean steady-state testosterone at week 6 of 422.4 ng/dL with 50 mg and 895.5 ng/dL with 100 mg [9].

What the label says to watch

The enanthate label directs deep intramuscular injection into the gluteal muscle [4]. It describes leg pain, swelling, warmth or redness and acute shortness of breath as findings to evaluate for a venous thromboembolism, and says to stop treatment and work up if one is suspected [4]. It also notes edema with or without heart failure in men with cardiac, renal or hepatic disease, gynecomastia that frequently develops and occasionally persists, and interactions with oral anticoagulants, insulin and antidiabetic drugs, corticosteroids and ACTH, and oxyphenbutazone [4].

The large cardiovascular trial, TRAVERSE, tested a daily 1.62% testosterone gel, not injections. Among 5,246 men, major adverse cardiovascular events occurred in 7.0% on testosterone versus 7.3% on placebo, hazard ratio 0.96 [10]. The Hikma enanthate label, effective May 2026, does not mention TRAVERSE. It still says studies have been inconclusive for major adverse cardiovascular events and that some studies, but not all, have reported an increased risk [4].